Antimicrobial Treatment of Severe Sepsis

Overview

Journal Antibiotics (Basel)

Specialty Pharmacology

Date 2022 Oct 27

PMID 36290092

Authors

Johnny Zakhour

Sima L Sharara

Joya-Rita Hindy

Sara F Haddad

Souha S Kanj

Affiliations

Soon will be listed here.

Abstract

is a pathogen often encountered in a healthcare setting. It has consistently ranked among the most frequent pathogens seen in nosocomial infections, particularly bloodstream and respiratory tract infections. Aside from having intrinsic resistance to many antibiotics, it rapidly acquires resistance to novel agents. Given the high mortality of pseudomonal infections generally, and pseudomonal sepsis particularly, and with the rise of resistant strains, treatment can be very challenging for the clinician. In this paper, we will review the latest evidence for the optimal treatment of sepsis caused by susceptible as well as multidrug-resistant strains including the difficult to treat pathogens. We will also discuss the mode of drug infusion, indications for combination therapy, along with the proper dosing and duration of treatment for various conditions with a brief discussion of the use of non-antimicrobial agents.

Citing Articles

Glutathione-Encoding Genes (gshA and gshB) are Associated with Oxidative Stress and Antibiotic Susceptibility in Pseudomonas aeruginosa.

Kwon D, Alsaleh S, Alharbi F, Almansour A Curr Microbiol. 2025; 82(4):138.

PMID: 39955681 DOI: 10.1007/s00284-025-04118-z.

Exploring the antibacterial and anti-biofilm activity of two Iranian medical-grade kinds of honey on multidrug-resistant Pseudomonas aeruginosa.

Alshaybawee M, Asgari S, Ghadersoltani P, Mehrabian A, Saniee P BMC Complement Med Ther. 2025; 25(1):39.

PMID: 39905465 PMC: 11792292. DOI: 10.1186/s12906-025-04778-1.

Characteristics of Pseudomonas aeruginosa keratitis at Ho Chi Minh eye hospital.

Nguyen P, Nguyen M, Nguyen X, Ngo T, Vu T, Duong T Int Ophthalmol. 2024; 45(1):9.

PMID: 39672962 DOI: 10.1007/s10792-024-03375-4.

Evolutionary loss of an antibiotic efflux pump increases quorum sensing mediated virulence .

Fernandes S, Ortega H, Vaillancourt M, Galdino A, Stotland A, Mun K Res Sq. 2024; .

PMID: 39606469 PMC: 11601840. DOI: 10.21203/rs.3.rs-5391023/v1.

Loss of PADI2 and PADI4 ameliorates sepsis-induced acute lung injury by suppressing NLRP3+ macrophages.

Yu X, Song Y, Dong T, Ouyang W, Shao L, Quan C JCI Insight. 2024; 9(22).

PMID: 39405117 PMC: 11601939. DOI: 10.1172/jci.insight.181686.

References

Gimeno C, Canton R, Garcia A, Gobernado M . [Comparative activity of doripenem, meropenem, and imipenem in recent clinical isolates obtained during the COMPACT-Spain epidemiological surveillance study]. Rev Esp Quimioter. 2010; 23(3):144-52. View

Cook R, Brown N, Redgwell T, Rihtman B, Barnes M, Clokie M . INfrastructure for a PHAge REference Database: Identification of Large-Scale Biases in the Current Collection of Cultured Phage Genomes. Phage (New Rochelle). 2022; 2(4):214-223. PMC: 9041510. DOI: 10.1089/phage.2021.0007. View

Lee M, Abbey T, Biagi M, Wenzler E . Activity of aztreonam in combination with ceftazidime-avibactam against serine- and metallo-β-lactamase-producing Pseudomonas aeruginosa. Diagn Microbiol Infect Dis. 2020; 99(1):115227. DOI: 10.1016/j.diagmicrobio.2020.115227. View

De Winter S, Wauters J, Meersseman W, Verhaegen J, Van Wijngaerden E, Peetermans W . Higher versus standard amikacin single dose in emergency department patients with severe sepsis and septic shock: a randomised controlled trial. Int J Antimicrob Agents. 2017; 51(4):562-570. DOI: 10.1016/j.ijantimicag.2017.11.009. View

Bach M, de Vries C, Khosravi A, Sweere J, Popescu M, Chen Q . Filamentous bacteriophage delays healing of Pseudomonas-infected wounds. Cell Rep Med. 2022; 3(6):100656. PMC: 9244996. DOI: 10.1016/j.xcrm.2022.100656. View

Xiao A, Miller B, Huntington J, Nicolau D . Ceftolozane/tazobactam pharmacokinetic/pharmacodynamic-derived dose justification for phase 3 studies in patients with nosocomial pneumonia. J Clin Pharmacol. 2015; 56(1):56-66. PMC: 5049594. DOI: 10.1002/jcph.566. View

Britt N, Ritchie D, Kollef M, Burnham C, Durkin M, Hampton N . Importance of Site of Infection and Antibiotic Selection in the Treatment of Carbapenem-Resistant Pseudomonas aeruginosa Sepsis. Antimicrob Agents Chemother. 2018; 62(4). PMC: 5913923. DOI: 10.1128/AAC.02400-17. View

Rhoads D, Wolcott R, Kuskowski M, Wolcott B, Ward L, Sulakvelidze A . Bacteriophage therapy of venous leg ulcers in humans: results of a phase I safety trial. J Wound Care. 2009; 18(6):237-8, 240-3. DOI: 10.12968/jowc.2009.18.6.42801. View

Tofas P, Samarkos M, Piperaki E, Kosmidis C, Triantafyllopoulou I, Kotsopoulou M . Pseudomonas aeruginosa bacteraemia in patients with hematologic malignancies: risk factors, treatment and outcome. Diagn Microbiol Infect Dis. 2017; 88(4):335-341. DOI: 10.1016/j.diagmicrobio.2017.05.003. View

10.

Song Y, Baer M, Srinivasan R, Lima J, Yarranton G, Bebbington C . PcrV antibody-antibiotic combination improves survival in Pseudomonas aeruginosa-infected mice. Eur J Clin Microbiol Infect Dis. 2011; 31(8):1837-45. DOI: 10.1007/s10096-011-1509-2. View

11.

Jernigan J, Hatfield K, Wolford H, Nelson R, Olubajo B, Reddy S . Multidrug-Resistant Bacterial Infections in U.S. Hospitalized Patients, 2012-2017. N Engl J Med. 2020; 382(14):1309-1319. PMC: 10961699. DOI: 10.1056/NEJMoa1914433. View

12.

Teo J, Lim J, Tang C, Lee S, Tan S, Sim J . Ceftolozane/Tazobactam Resistance and Mechanisms in Carbapenem-Nonsusceptible Pseudomonas aeruginosa. mSphere. 2021; 6(1). PMC: 7885320. DOI: 10.1128/mSphere.01026-20. View

13.

Abdul-Aziz M, Sulaiman H, Mat-Nor M, Rai V, Wong K, Hasan M . Beta-Lactam Infusion in Severe Sepsis (BLISS): a prospective, two-centre, open-labelled randomised controlled trial of continuous versus intermittent beta-lactam infusion in critically ill patients with severe sepsis. Intensive Care Med. 2016; 42(10):1535-1545. DOI: 10.1007/s00134-015-4188-0. View

14.

Bassetti M, Righi E, Carnelutti A . Bloodstream infections in the Intensive Care Unit. Virulence. 2016; 7(3):267-79. PMC: 4871677. DOI: 10.1080/21505594.2015.1134072. View

15.

Aloush V, Navon-Venezia S, Seigman-Igra Y, Cabili S, Carmeli Y . Multidrug-resistant Pseudomonas aeruginosa: risk factors and clinical impact. Antimicrob Agents Chemother. 2005; 50(1):43-8. PMC: 1346794. DOI: 10.1128/AAC.50.1.43-48.2006. View

16.

Magill S, Edwards J, Bamberg W, Beldavs Z, Dumyati G, Kainer M . Multistate point-prevalence survey of health care-associated infections. N Engl J Med. 2014; 370(13):1198-208. PMC: 4648343. DOI: 10.1056/NEJMoa1306801. View

17.

Shiu J, Wang E, Tejani A, Wasdell M . Continuous versus intermittent infusions of antibiotics for the treatment of severe acute infections. Cochrane Database Syst Rev. 2013; (3):CD008481. PMC: 8946287. DOI: 10.1002/14651858.CD008481.pub2. View

18.

Hanberger H, Giske C, Giamarellou H . When and how to cover for resistant gram-negative bacilli in severe sepsis and septic shock. Curr Infect Dis Rep. 2011; 13(5):416-25. DOI: 10.1007/s11908-011-0200-1. View

19.

Carmeli Y, Troillet N, Eliopoulos G, Samore M . Emergence of antibiotic-resistant Pseudomonas aeruginosa: comparison of risks associated with different antipseudomonal agents. Antimicrob Agents Chemother. 1999; 43(6):1379-82. PMC: 89282. DOI: 10.1128/AAC.43.6.1379. View

20.

Vardakas K, Voulgaris G, Maliaros A, Samonis G, Falagas M . Prolonged versus short-term intravenous infusion of antipseudomonal β-lactams for patients with sepsis: a systematic review and meta-analysis of randomised trials. Lancet Infect Dis. 2017; 18(1):108-120. DOI: 10.1016/S1473-3099(17)30615-1. View